Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer
Explore this paper's citation graph
Summary
This study compared the efficacy and tolerability of Docetaxel, and fluorouracil Carboplatin (DF-Carbo regimen) with that of the reference protocol of epirubicin, cisplatin and fluorouredacil (ECF regimen).
- Type
- article
- Published
- 2005-06-01
- Cited by
- 24
- References
- 0
- OpenAlex
- https://openalex.org/W1887261193
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:70532342
Keywords
Docetaxel, Epirubicin, Medicine, Regimen, Carboplatin
References
No references recorded for this paper.
Cited by
- Role of radiation therapy in gastric adenocarcinoma.
- Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.
- Chemotherapy for advanced gastric cancer.
- Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer
- Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
- Clinical implications of genetic polymorphisms on stomach cancer drug therapy
- Docetaxel in the treatment of gastric cancer.
- Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer
- Systemic therapy for advanced gastric cancer: a clinical practice guideline.
- Advanced gastric cancer--slow but steady progress.
- Recent developments in the systemic therapy of advanced gastroesophageal malignancies
- Challenges in the treatment of gastrointestinal tumours.
- Evolving chemotherapy for advanced gastric cancer.
- The clinical significance of chemotherapy in patients with advanced gastric cancer
- Fortschritte in der systemischen Therapie des metastasierten Magenkarzinoms
- Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follow‐Up
- The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
- Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines
- Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Related papers
- TS-1 による術後補助療法中に発症しWeekly Docetaxel 療法により著効をみた胃癌腹膜播種の1 例
- The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel.
- Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions.
- Primary chemotherapy with sequential docetaxel followed by docetaxel and epirubicin in large operable breast cancer.
- Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer.
- FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy.
- 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
- Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer.